Bevacizumab

Drug Profile

Bevacizumab

Alternative Names: Avastin; RG-435; rhuMAb-VEGF; RO-4876646

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Genentech; Hackensack University Medical Center
  • Developer All Ireland Cooperative Oncology Research Group; Austrian Breast & Colorectal Cancer Study Group; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Japan Breast Cancer Research Group; Massachusetts General Hospital; Medical University of South Carolina; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; NSABP Foundation; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Mesothelioma; Cervical cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase III Head and neck cancer; Mesothelioma
  • Phase II Brain metastases; Fallopian tube cancer; Gynaecological cancer; Hepatocellular carcinoma; Liver cancer; Liver metastases; Malignant melanoma; Multiple myeloma; Neuroblastoma; Neurofibromatoses; Peritoneal cancer; Rectal cancer; Soft tissue sarcoma
  • Phase I/II Neoplastic meningitis
  • Suspended Carcinoid tumour
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye disorders; Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 22 Dec 2016 Bevacizumab receives Orphan Drug status for Mesothelioma (Metastatic disease) in Japan
  • 06 Dec 2016 Bevacizumab receives priority review status for Ovarian, fallopian tube or primary peritoneal cancer (combination therapy, recurrent, platinum-sensitive) in USA before December 2016
  • 06 Dec 2016 The US FDA approves bevacizumab (either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone) for Ovarian cancer (platinum-sensitive recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top